# India Pharmaceuticals Industry > India Pharmaceuticals Industry Market Research Report: Size, Share, Trend Analysis By Therapeutic Category (Anti-Infectives, Cardiovascular, Gastrointestinal, Anti Diabetic, Respiratory, Dermatological, Musculo-Skeletal System, Nervous System, Others), By Drug Type (Prescription Drug, OTC Drugs) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.09% - **2023:** $ 55.97 Billion - **2024:** $ 42.5 Billion - **2035:** $ 100 Billion - **Key Players:** Companies such as GlaxoSmithKline plc6., Biocon Limited6., Pfizer Inc6., Novartis AG6., Merck & Co., Inc., Torrent Pharma., Divi's Laboratories, Aurobindo Pharma Limited, Mankind Pharma, Abbott are some of the major participants in the India Pharmaceuticals Industry Market. **Report ID:** MRFR/HC/20205-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** June 26, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-pharmaceuticals-industry-21803 --- ## Market Summary ## **India Pharmaceuticals Industry Market Overview** As per MRFR analysis, the India Pharmaceuticals Industry Market Size was estimated at 55.97 (USD Billion) in 2023. The India Pharmaceuticals Industry Market Industry is expected to grow from 62.14 (USD Billion) in 2024 to 132.72 (USD Billion) by 2032. The Market CAGR (growth rate) is expected to be around 8.80% during the forecast period (2024 - 2032). Rising rates of chronic illnesses and rising pharmaceutical product demand are the main market drivers anticipated to propel the pharmaceuticals industry market in India. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **India Pharmaceuticals Industry Market Trends** ### **Growing chronic illnesses are driving the market growth** A respiratory ailment is one that affects the lungs and respiratory tract. Infections, tobacco use, smoking, radon, asbestos, passive smoking, and other types of air pollution all contribute to these disorders. Lung cancer, pulmonary fibrosis, pneumonia, asthma, and chronic obstructive pulmonary disease (COPD) are among the common respiratory illnesses. Because air pollution is increasing and respiratory ailments are becoming more common, as well as ongoing research and development in the field and the introduction of new products into the Indian market, it is projected that the respiratory segment will grow at a substantial rate over the course of the forecast period. The Indian pharmaceutical industry has a long history of creating and exporting top-notch goods at competitive prices to customers all over the world. India possesses the highest number of US FDA-approved units (741 as of August 2021) according to IBEF statistics revised in June 2022. Pharmaceutical firms based in India provide products in several categories, including over-the-counter (OTC) medications, vaccines, active pharmaceutical ingredients (APIs), contract research and manufacture, biosimilars, and biologics. Furthermore, the pharmaceutical sector is significantly shaped by government laws and regulations. The dynamics and growth trajectory of the industry are affected by policies pertaining to drug approvals, pricing, intellectual property rights, and foreign direct investment (FDI). India has a sizable middle class with rising purchasing power, significant healthcare requirements, and a vast population. Due to the large market this generates for pharmaceutical goods and services, there is a need for them and room for expansion. India has a competitive edge over many other nations in the production of generic medications and the execution of clinical trials at a reduced cost due to its competent workforce and cost-effective manufacturing capabilities. Pharmaceutical firms, both domestic and international, invest in research and development (R&D) to foster creativity, develop new products, and enhance technology, which drives the market CAGR. For instance, as per the IBEF, the pharmaceutical and drug exports for the years 2021–22 amounted to USD 24.6 billion, while for the years 2020–21 they were USD 24.4 billion. Approval times for new facilities have been shortened in order to attract investment. ## **India Pharmaceuticals Industry Market Segment Insights** ### **India Pharmaceuticals Industry Therapeutic Category Insights** The India Pharmaceuticals Industry market segmentation, based on Therapeutic Category includes Anti-Infectives, Cardiovascular, Gastrointestinal,[Oral Anti Diabetic](../../../reports/oral-anti-diabetic-drug-market-42273), Respiratory, Dermatological, Musculo-Skeletal System, Nervous System, and Others. The cardiovascular segment dominated the market mostly. Because pharmaceuticals classified as cardiovascular meds mostly affect the heart or blood arteries. They are used to treat heart and circulation-related ailments. Examples include antiarrhythmics. ### **India Pharmaceuticals Industry Drug Type Insights** The India Pharmaceuticals Industry market segmentation, based on Drug Type, includes Prescription Drug and OTC Drugs. The OTC drugs category generated the most income. This is because over-the-counter medications are those that do not require a prescription to purchase and are typically safe to use without a doctor's supervision. Usually, they are used to treat mild illnesses and symptoms. Acetaminophen and diphenhydramine are two examples. **Figure 1: India Pharmaceuticals Industry Market, by Drug Type, 2022 & 2032 (USD Billion)** **** Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **India Pharmaceuticals Industry Country Insights** India has a large population, which generates a sizable home market for pharmaceuticals. The rise of the domestic market is facilitated by the growing middle class and rising awareness of healthcare issues. A number of variables, including lower labor costs, relatively cheap raw materials, and a supportive regulatory environment, give India a competitive edge when it comes to manufacturing prices. In comparison to many other nations, this enables Indian pharmaceutical companies to develop pharmaceuticals at reduced costs. India is becoming a top choice for businesses globally looking to outsource their pharmaceutical research and production operations. For multinational pharmaceutical companies trying to cut production costs, its highly qualified workforce, cutting-edge infrastructure, and affordable services make it a desirable choice. India has a thriving generic medication market that creates reasonably priced substitutes. ## **India Pharmaceuticals Industry Key Market Players & Competitive Insights** Leading market players are putting a lot of money in R&D to increase the range of products they sell, which will support further growth in the Indian pharmaceutical industry. Additionally, market players are engaging in a range of calculated actions to increase their presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To expand and survive in a more competitive and rising market climate, India Pharmaceuticals industry must offer cost-effective items. Major players in the India Pharmaceuticals Industry market are attempting to increase market demand by investing in research and development operations includes GlaxoSmithKline plc6., Biocon Limited6., Pfizer Inc6., Novartis AG6., Merck & Co., Inc., Torrent Pharma., Divi's Laboratories, Aurobindo Pharma Limited, Mankind Pharma, Abbott. ### **Key Companies in the India Pharmaceuticals Industry market include** - Cipla Inc. - Dr. Reddy's Laboratories Ltd. - Lupin Limited. - UN Pharmaceutical Industries Ltd. - Cadila Pharmaceuticals. - GlaxoSmithKline plc. - Biocon Limited. - [Pfizer Inc.](https://www.pfizer.co.in/about-us/pfizer-in-india) - Novartis AG. - Merck & Co., Inc. - Torrent Pharma. - Divi's Laboratories - Aurobindo Pharma Limited - Mankind Pharma - Abbott ## **India Pharmaceuticals Industry Industry Developments** In March 2024, Sun Pharmaceutical Industries added a new drug as a biosimilar for the patients diagnosed with rheumatoid arthritis. This biosimilar is said to focus on the cheap but effective biologic market which is gaining demand. In January 2024, Indian players in the pharmaceutical industry started making notable strides in automating drug production processes. Players like Cipla and Lupin started putting money in AI inspired factories with the aim to optimize drug manufacturing processes and cut down the cost of drug production. ## **India Pharmaceuticals Industry Market Segmentation** ### **India Pharmaceuticals Industry Therapeutic Category Outlook** - Anti-Infectives - Cardiovascular - Gastrointestinal - Anti Diabetic - Respiratory - Dermatological - Musculo-Skeletal System - Nervous System - Others ### **India Pharmaceuticals Industry Drug Type Outlook** - Prescription Drug - OTC Drugs ## Market Drivers ### Market Growth Projections The Global India Pharmaceuticals Industry Market is projected to experience substantial growth, with forecasts indicating a market size of 42.5 USD Billion in 2024 and a potential reach of 100 USD Billion by 2035. The anticipated compound annual growth rate of 8.09% from 2025 to 2035 underscores the market's resilience and adaptability.   This growth trajectory reflects the increasing demand for pharmaceuticals, driven by factors such as population growth, rising healthcare expenditures, and advancements in medical technology. The market's expansion is indicative of India's strategic importance in the global pharmaceutical landscape. ### Rising Export Opportunities Rising export opportunities are significantly contributing to the Global India Pharmaceuticals Industry Market. India is recognized as a leading exporter of pharmaceuticals, supplying to over 200 countries. The increasing global demand for affordable medications, particularly in emerging markets, is likely to bolster India's export capabilities.   The market's growth is further supported by favorable trade agreements and collaborations with international organizations. As the global healthcare landscape evolves, India's pharmaceutical exports are expected to expand, enhancing the market's overall value and positioning India as a key player in the global pharmaceutical supply chain. ### Advancements in Biotechnology Advancements in biotechnology are significantly influencing the Global India Pharmaceuticals Industry Market. The integration of biopharmaceuticals, which are derived from biological sources, is expanding the treatment landscape for various diseases.   The market is expected to evolve with innovative therapies that address unmet medical needs, potentially leading to a market size of 100 USD Billion by 2035. The Indian biotechnology sector is increasingly collaborating with global firms, fostering research and development that enhances the efficacy and safety of new drugs, thereby driving market growth. ### Growing Demand for Generic Drugs The Global India Pharmaceuticals Industry Market is witnessing a robust demand for generic drugs, primarily due to their affordability and accessibility. With the Indian government promoting the use of generics, the market is projected to reach 42.5 USD Billion in 2024.   This shift towards generics is driven by rising healthcare costs globally, compelling patients and healthcare providers to seek cost-effective alternatives. Furthermore, the increasing prevalence of chronic diseases necessitates a broader range of affordable medication options, thereby enhancing the market's growth potential. ### Government Initiatives and Policies Government initiatives and policies play a crucial role in shaping the Global India Pharmaceuticals Industry Market. The Indian government has implemented various schemes aimed at boosting domestic manufacturing and reducing dependency on imports.   Initiatives such as the Production Linked Incentive scheme encourage pharmaceutical companies to enhance production capabilities. These policies are likely to create a conducive environment for growth, with the market projected to grow at a CAGR of 8.09% from 2025 to 2035. Such supportive measures are essential for positioning India as a global hub for pharmaceuticals. ### Increasing Investment in Research and Development Investment in research and development is a key driver for the Global India Pharmaceuticals Industry Market. Pharmaceutical companies are increasingly allocating resources to develop innovative drugs and therapies, which is vital for maintaining competitive advantage.   The focus on R&D is expected to yield breakthroughs in [drug development](https://www.marketresearchfuture.com/reports/drug-development-market-66529), enhancing the overall market landscape. As companies strive to meet global health challenges, the emphasis on R&D could contribute to the market's growth trajectory, potentially reaching 100 USD Billion by 2035. This investment not only fosters innovation but also strengthens India's position in the global pharmaceutical arena. ## Future Outlook The India Pharmaceuticals Industry Market size is projected to reach USD 100 Billion by 2035, growing at a CAGR of 8.09%. **New opportunities:** - Invest in biopharmaceuticals to leverage advancements in personalized medicine. Expand telehealth services to enhance patient engagement and accessibility. Develop sustainable packaging solutions to meet environmental regulations and consumer preferences. By 2035, the India Pharmaceuticals Industry Market is expected to achieve substantial growth, positioning itself as a global leader. ## Segment Insights ### India Pharmaceuticals Industry Market Therapeutic Category Insights The India Pharmaceuticals Industry Market segmentation, based on Therapeutic Category includes Anti-Infectives, Cardiovascular, Gastrointestinal, Oral Anti Diabetic, Respiratory, Dermatological, Musculo-Skeletal System, Nervous System, and Others. The cardiovascular segment dominated the market mostly with the market share of 18%. Because pharmaceuticals classified as cardiovascular meds mostly affect the heart or blood arteries. They are used to treat heart and circulation-related ailments. Examples include antiarrhythmics. ### India Pharmaceuticals Industry Market Drug Type Insights The India Pharmaceuticals Industry Market segmentation, based on Drug Type, includes Prescription Drug and OTC Drugs. The OTC drugs category generated the most income with market share of 57%. This is because over-the-counter medications are those that do not require a prescription to purchase and are typically safe to use without a doctor's supervision. Usually, they are used to treat mild illnesses and symptoms. Acetaminophen and diphenhydramine are two examples. Figure 1: India Pharmaceuticals Industry Market, by Drug Type, 2022 & 2032 (USD Billion) Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review ### India Pharmaceuticals Industry Market Country Insights India has a large population, which generates a sizable home market for pharmaceuticals. The rise of the domestic market is facilitated by the growing middle class and rising awareness of healthcare issues. A number of variables, including lower labor costs, relatively cheap raw materials, and a supportive regulatory environment, give India a competitive edge when it comes to manufacturing prices. In comparison to many other nations, this enables Indian pharmaceutical companies to develop pharmaceuticals at reduced costs. India is becoming a top choice for businesses globally looking to outsource their pharmaceutical research and production operations. For multinational pharmaceutical companies trying to cut production costs, its highly qualified workforce, cutting-edge infrastructure, and affordable services make it a desirable choice. India has a thriving generic medication market that creates reasonably priced substitutes. ## Competitive Benchmarking Leading market players are putting a lot of money in R&D to increase the range of products they sell, which will support further growth in the Indian pharmaceutical industry. Additionally, market players are engaging in a range of calculated actions to increase their presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises.   To expand and survive in a more competitive and rising market climate, India Pharmaceuticals industry must offer cost-effective items.Major players in the India Pharmaceuticals Industry Market are attempting to increase market demand by investing in research and development operations includes GlaxoSmithKline plc6., Biocon Limited6., Pfizer Inc6., Novartis AG6., Merck & Co., Inc., Torrent Pharma., Divi's Laboratories, Aurobindo Pharma Limited, Mankind Pharma, Abbott. ## Recent News & Developments In March 2024, Sun Pharmaceutical Industries added a new drug as a biosimilar for the patients diagnosed with rheumatoid arthritis. This biosimilar is said to focus on the cheap but effective biologic market which is gaining demand. In January 2024, Indian players in the pharmaceutical industry started making notable strides in automating drug production processes. Players like Cipla and Lupin started putting money in AI inspired factories with the aim to optimize drug manufacturing processes and cut down the cost of drug production. ## Report Scope | Report Attribute/Metric | Details | | --- | --- | | Market Size 2023 | USD 55.97 Billion | | Market Size 2024 | USD 62.14 Billion | | Market Size 2032 | USD 132.72 Billion | | Compound Annual Growth Rate (CAGR) | 8.80% (2023-2032) | | Base Year | 2022 | | Market Forecast Period | 2023-2032 | | Historical Data | 2018-2022 | | Market Forecast Units | Value (USD Billion) | | Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends | | Segments Covered | Therapeutic Category, Drug Type, and Region | | Countries Covered | India | | Key Companies Profiled | GlaxoSmithKline plc6., Biocon Limited6., Pfizer Inc6., Novartis AG6., Merck & Co., Inc., Torrent Pharma., Divi's Laboratories, Aurobindo Pharma Limited, Mankind Pharma, Abbott | | Key Market Opportunities | Increasing prevalence of chronic diseases ·Rise the demand for pharmaceutical products | | Key Market Dynamics | Rising healthcare expenditures contribute to the demand for innovative pharmaceutical solutions ·         Rising incomes, expanding middle-class populations, and increasing access to healthcare | ## Frequently Asked Questions **Q: How much is the India Pharmaceuticals Industry market?** A: The India Pharmaceuticals Industry market size was valued at USD 55.97 Billion in 2023. **Q: What is the growth rate of the India Pharmaceuticals Industry market?** A: Throughout the predicted period of 2023–2032, the market is expected to develop at a CAGR of 8.80%. **Q: Who are the key players in the India Pharmaceuticals Industry market?** A: The key players in the market are GlaxoSmithKline plc6., Biocon Limited6., Pfizer Inc6., Novartis AG6., Merck & Co., Inc., Torrent Pharma., Divi's Laboratories, Aurobindo Pharma Limited, Mankind Pharma, Abbott. **Q: Which Therapeutic Category led the India Pharmaceuticals Industry market?** A: The Cardiovascular category dominated the market in 2022. **Q: Which kind of medication held the biggest market share in India's pharmaceutical sector?** A: The OTC Drugs had the largest share in the market. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-pharmaceuticals-industry-21803*